Published in J Neurochem on March 01, 1994
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol (2013) 4.16
Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS One (2011) 2.30
Direct and potent regulation of gamma-secretase by its lipid microenvironment. J Biol Chem (2008) 2.00
Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci U S A (1995) 1.91
Role of ganglioside metabolism in the pathogenesis of Alzheimer's disease--a review. J Lipid Res (2008) 1.68
Roles for dysfunctional sphingolipid metabolism in Alzheimer's disease neuropathogenesis. Biochim Biophys Acta (2010) 1.56
Multi-dimensional mass spectrometry-based shotgun lipidomics and the altered lipids at the mild cognitive impairment stage of Alzheimer's disease. Biochim Biophys Acta (2010) 1.24
Soluble Aβ oligomers are rapidly sequestered from brain ISF in vivo and bind GM1 ganglioside on cellular membranes. Neuron (2014) 1.19
Redox reactions of copper complexes formed with different beta-amyloid peptides and their neuropathological [correction of neuropathalogical] relevance. Biochemistry (2007) 1.12
Molecular insights into amyloid regulation by membrane cholesterol and sphingolipids: common mechanisms in neurodegenerative diseases. Expert Rev Mol Med (2010) 1.04
Brain pathology in Niemann Pick disease type A: insights from the acid sphingomyelinase knockout mice. J Neurochem (2011) 0.97
Lipidomic analysis of brain tissues and plasma in a mouse model expressing mutated human amyloid precursor protein/tau for Alzheimer's disease. Lipids Health Dis (2013) 0.97
Ternary complexes of iron, amyloid-beta, and nitrilotriacetic acid: binding affinities, redox properties, and relevance to iron-induced oxidative stress in Alzheimer's disease. Biochemistry (2009) 0.96
Evidence that Perutz's double-beta-stranded subunit structure for beta-amyloids also applies to their channel-forming structures in membranes. Proc Natl Acad Sci U S A (2006) 0.94
Ganglioside metabolism in a transgenic mouse model of Alzheimer's disease: expression of Chol-1α antigens in the brain. ASN Neuro (2010) 0.91
Modifications of glycans: biological significance and therapeutic opportunities. ACS Chem Biol (2012) 0.90
The role of APP proteolytic processing in lipid metabolism. Exp Brain Res (2011) 0.90
The interaction of beta-amyloid protein fragment (12-28) with lipid environments. Protein Sci (1997) 0.88
Disturbed choline plasmalogen and phospholipid fatty acid concentrations in Alzheimer's disease prefrontal cortex. J Alzheimers Dis (2011) 0.87
Effects of amyloid beta-peptides on the lysis tension of lipid bilayer vesicles containing oxysterols. Biophys J (2008) 0.86
Amyloid β-peptide 1-42 modulates the proliferation of mouse neural stem cells: upregulation of fucosyltransferase IX and notch signaling. Mol Neurobiol (2014) 0.84
The pathological roles of ganglioside metabolism in Alzheimer's disease: effects of gangliosides on neurogenesis. Int J Alzheimers Dis (2011) 0.83
Activity and architecture of pyroglutamate-modified amyloid-β (AβpE3-42) pores. J Phys Chem B (2014) 0.83
Metabolic interaction between ApoE genotype and onset age in Alzheimer's disease: implications for brain reserve. J Neurol Neurosurg Psychiatry (2005) 0.83
Epidemiology of early-onset dementia: a review of the literature. Clin Pract Epidemiol Ment Health (2013) 0.83
Myelin basic protein associates with AβPP, Aβ1-42, and amyloid plaques in cortex of Alzheimer's disease brain. J Alzheimers Dis (2015) 0.83
Effects of amyloid β-peptides and gangliosides on mouse neural stem cells. Neurochem Res (2013) 0.81
HFE gene variants, iron, and lipids: a novel connection in Alzheimer's disease. Front Pharmacol (2014) 0.81
The pathogenic implication of abnormal interaction between apolipoprotein E isoforms, amyloid-beta peptides, and sulfatides in Alzheimer's disease. Mol Neurobiol (2010) 0.80
Possible modification of Alzheimer's disease by statins in midlife: interactions with genetic and non-genetic risk factors. Front Aging Neurosci (2014) 0.80
Apolipoprotein serum amyloid A down-regulates smooth-muscle cell lipid biosynthesis. Biochem J (1999) 0.79
Effect of Different Phospholipids on α-Secretase Activity in the Non-Amyloidogenic Pathway of Alzheimer's Disease. Int J Mol Sci (2013) 0.79
Alois Alzheimer revisited: differences in origin of the disease carrying his name. J Neural Transm (Vienna) (2006) 0.79
The modulating effect of mechanical changes in lipid bilayers caused by apoE-containing lipoproteins on Aβ induced membrane disruption. ACS Chem Neurosci (2011) 0.78
Age- and brain region-specific effects of dietary vitamin K on myelin sulfatides. J Nutr Biochem (2010) 0.78
Alterations in mouse brain lipidome after disruption of CST gene: a lipidomics study. Mol Neurobiol (2014) 0.77
Deficiency of Lipoprotein Lipase in Neurons Decreases AMPA Receptor Phosphorylation and Leads to Neurobehavioral Abnormalities in Mice. PLoS One (2015) 0.77
Increased Expression of Simple Ganglioside Species GM2 and GM3 Detected by MALDI Imaging Mass Spectrometry in a Combined Rat Model of Aβ Toxicity and Stroke. PLoS One (2015) 0.77
Modeling cholesterol metabolism by gene expression profiling in the hippocampus. Mol Biosyst (2011) 0.76
Modification and inactivation of Cu,Zn-superoxide dismutase by the lipid peroxidation product, acrolein. BMB Rep (2013) 0.76
Changes in lipid membranes may trigger amyloid toxicity in Alzheimer's disease. PLoS One (2017) 0.76
APP Function and Lipids: A Bidirectional Link. Front Mol Neurosci (2017) 0.75
Hippocampal lipid differences in Alzheimer's disease: a human brain study using matrix-assisted laser desorption/ionization-imaging mass spectrometry. Brain Behav (2016) 0.75
Molecular interactions of amyloid nanofibrils with biological aggregation modifiers: implications for cytotoxicity mechanisms and biomaterial design. Interface Focus (2017) 0.75
Delineating Amyloid Plaque Associated Neuronal Sphingolipids In Transgenic Alzheimer's Disease Mice (tgArcSwe) Using MALDI Imaging Mass Spectrometry. ACS Chem Neurosci (2016) 0.75
Expression of B4GALNT1, an essential glycosyltransferase for the synthesis of complex gangliosides, suppresses BACE1 degradation and modulates APP processing. Sci Rep (2016) 0.75
Novel molecular insights into the critical role of sulfatide in myelin maintenance/function. J Neurochem (2016) 0.75
Impact of GM1 on Membrane-mediated Aggregation/Oligomerization of β-amyloid: Unifying View. Biophys J (2017) 0.75
White-matter lesions on CT in Alzheimer patients: relation to clinical symptomatology and vascular factors. Acta Neurol Scand (1991) 1.77
Changes in the brain catecholamines in patients with dementia of Alzheimer type. Br J Psychiatry (1979) 1.71
A population study on blood-brain barrier function in 85-year-olds: relation to Alzheimer's disease and vascular dementia. Neurology (1998) 1.50
The role of amyloid beta-protein in Alzheimer's disease. Lancet (1992) 1.49
A double-blind evaluation of electroconvulsive therapy in Parkinson's disease with "on-off" phenomena. Acta Neurol Scand (1987) 1.36
Blood-brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors. Acta Neurol Scand (1990) 1.29
Homovanillic acid and 5-hydroxyindoleacetic acid in the cerebrospinal fluid of patients with senile dementia, presenile dementia and parkinsonism. J Neurochem (1969) 1.21
Vitamin B12-B6-folate treatment improves blood-brain barrier function in patients with hyperhomocysteinaemia and mild cognitive impairment. Dement Geriatr Cogn Disord (2003) 1.20
A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand (1992) 1.18
Slowed synthesis of DNA and methionine is a pathogenetic mechanism common to dementia in Down's syndrome, AIDS and Alzheimer's disease? Med Hypotheses (1992) 1.15
Determination of 5-hydroxytryptamine, 5-hydroxyindoleacetic acid and homovanillic acid in brain tissue from an autopsy material. Acta Psychiatr Scand (1974) 1.14
The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Br J Psychiatry (1990) 1.14
Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18-88 years of age. Eur Neurol (1993) 1.13
Identification of cognitive impairment in the elderly: homocysteine is an early marker. Dement Geriatr Cogn Disord (1999) 1.11
Treatment of Alzheimer's disease with clioquinol. Dement Geriatr Cogn Disord (2001) 1.10
Blood brain barrier function in vascular dementia. Acta Neurol Scand (1990) 1.06
The Gottfries-Bråne-Steen scale: validity, reliability and application in anti-dementia drug trials. Dement Geriatr Cogn Disord (2001) 1.05
A new rating scale for dementia syndromes. Arch Gerontol Geriatr (1982) 1.05
Studies on duration of a late recovery period after chronic abuse of ethanol. A cross-sectional study of biochemical and psychiatric indicators. Acta Psychiatr Scand (1982) 1.00
Increased concentrations of homocysteine in the cerebrospinal fluid in patients with fibromyalgia and chronic fatigue syndrome. Scand J Rheumatol (1997) 0.99
The exfoliation syndrome in cognitive impairment of cerebrovascular or Alzheimer's type. Acta Ophthalmol Scand (2001) 0.99
Homocysteinemia and schizophrenia as a case of methylation deficiency. J Neural Transm Gen Sect (1994) 0.98
Biogenic amines in human brain in normal aging, senile dementia, and chronic alcoholism. Adv Biochem Psychopharmacol (1980) 0.97
Post-mortem distribution of dopamine and homovanillic acid in human brain, variations related to age, and a review of the literature. J Neural Transm (1979) 0.96
Changes in uptake of vitamin B(12) and trace metals in brains of mice treated with clioquinol. J Neurol Sci (2000) 0.96
Advanced catecholaminergic disturbances in the brain in a case of Wilson's disease. Acta Neurol Scand (1982) 0.96
Low blood pressure and blood glucose levels in Alzheimer's disease. Evidence for a hypometabolic disorder? J Intern Med (1993) 0.94
Protein analyses in cerebrospinal fluid. I. Influence of concentration gradients for proteins on cerebrospinal fluid/serum albumin ratio. Eur Neurol (1993) 0.94
Dexamethasone suppression test and serum prolactin in dementia disorders. Br J Psychiatry (1983) 0.94
Cerebrospinal fluid monoamine metabolites in 114 healthy individuals 18-88 years of age. Eur Neuropsychopharmacol (1993) 0.93
Acid monoamine metabolites in human cerebrospinal fluid and their relations to age and sex. Neuropharmacology (1971) 0.92
The synaptic-vesicle-specific proteins rab3a and synaptophysin are reduced in thalamus and related cortical brain regions in schizophrenic brains. Schizophr Res (1999) 0.92
Calpain and calpastatin in normal and Alzheimer-degenerated human brain tissue. Neurobiol Aging (1990) 0.91
Chlorpromazine-induced antinuclear factors. Acta Med Scand (1970) 0.91
Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT). Neurobiol Aging (1983) 0.91
Increased activity of brain and platelet monoamine oxidase in dementia of Alzheimer type. Life Sci (1980) 0.91
Stepwise comparative status analysis (STEP): a tool for identification of regional brain syndromes in dementia. J Geriatr Psychiatry Neurol (1996) 0.90
Delirium in dementia. Int J Geriatr Psychiatry (1998) 0.90
Reduced concentrations of galanin, arginine vasopressin, neuropeptide Y and peptide YY in the temporal cortex but not in the hypothalamus of brains from schizophrenics. Acta Psychiatr Scand (1991) 0.90
Superoxide dismutase isoenzymes in normal brains and in brains from patients with dementia of Alzheimer type. J Neurol Sci (1985) 0.88
Decreased myelin lipids in Alzheimer's disease and vascular dementia. Acta Neurol Scand (1989) 0.88
Intrathecal synthesis of immunoglobulins in patients with Alzheimer's disease. Eur Neuropsychopharmacol (1990) 0.88
Low platelet monoamine oxidase activity in human alcoholics. Med Biol (1977) 0.87
Immunocytochemical investigations on the presence of neuron-specific antibodies in the CSF of Parkinson's disease cases. Neurochem Res (1988) 0.87
Gangliosides in cerebrospinal fluid in 'probable Alzheimer's disease'. Arch Neurol (1991) 0.86
Immune modulation with a staphylococcal preparation in fibromyalgia/chronic fatigue syndrome: relation between antibody levels and clinical improvement. Eur J Clin Microbiol Infect Dis (2004) 0.86
Quantitative changes in the amyloid beta A4 precursor protein in Alzheimer cerebrospinal fluid. Neurosci Lett (1991) 0.86
Monoamine oxidase B in brains from patients with Alzheimer's disease: a biochemical and autoradiographical study. Neuroscience (1991) 0.85
Homovanillic acid and 5-hydroxyindoleacetic acid in cerebrospinal fluid related to rated mental and motor impairment in senile and presenile dementia. Acta Psychiatr Scand (1970) 0.85
Pharmacokinetic studies on flupenthixol and flupenthixol decanoate in man using tritium labelled compounds. Psychopharmacologia (1972) 0.85
White matter low attenuation on computed tomography in Alzheimer's disease and vascular dementia--diagnostic and pathogenetic aspects. Acta Neurol Scand (1989) 0.85
Diagnosis of dementias using partial least squares discriminant analysis. Dementia (1995) 0.85
Prevalence of dementia disorders in institutionalized Swedish old people. The work load imposed by caring for these patients. Acta Psychiatr Scand (1981) 0.84
Putamen mitochondrial energy metabolism is highly correlated to emotional and intellectual impairment in schizophrenics. Neuropsychopharmacology (2000) 0.84
Long-term treatment of elderly individuals with emotional disturbances: an open study with citalopram. Int Psychogeriatr (1996) 0.84
A new rating scale for dementia syndromes. Gerontology (1982) 0.84
The investigation of homovanillic acid in the human brain and its correlation to senile dementia. Br J Psychiatry (1969) 0.83
Brain and brain monoamine oxidase in aging and in dementia of Alzheimer's type. Prog Neuropsychopharmacol Biol Psychiatry (1986) 0.83
Sulfatide as a biochemical marker in cerebrospinal fluid of patients with vascular dementia. Acta Neurol Scand (1992) 0.83
Confusional State Evaluation (CSE): an instrument for measuring severity of delirium in the elderly. Br J Psychiatry (1997) 0.83
Cerebrospinal fluid pH and monoamine and glucolytic metabolites in Alzheimer's disease. Br J Psychiatry (1974) 0.83
Ubiquitin in cerebrospinal fluid in Alzheimer's disease and vascular dementia. Int Psychogeriatr (1994) 0.83
Lowered monoamine oxidase activity in brains from alcoholic suicides. J Neurochem (1975) 0.83
Mitochondrial function is differentially altered in the basal ganglia of chronic schizophrenics. Neuropsychopharmacology (1999) 0.83
Hyperactivity in the hypothalamic-pituitary-adrenal axis in demented patients with delirium. Int Clin Psychopharmacol (2001) 0.83
Reduction of chromogranin A and B but not C in the cerebrospinal fluid in subjects with schizophrenia. Eur Neuropsychopharmacol (1999) 0.82
Intra-blood-brain-barrier synthesis of immunoglobulins in patients with dementia of the Alzheimer type. Alzheimer Dis Assoc Disord (1990) 0.82
Alzheimer's disease and senile dementia: biochemical characteristics and aspects of treatment. Psychopharmacology (Berl) (1985) 0.82
Changes in dopamine receptor sensitivity in humans after heavy alcohol intake. Psychopharmacology (Berl) (1985) 0.82
Concentration gradients for monoamine metabolites in lumbar cerebrospinal fluid. J Neural Transm Park Dis Dement Sect (1993) 0.82
Significance of decreased lumbar CSF levels of HVA and 5-HIAA in Alzheimer's disease. Neurobiol Aging (1992) 0.81
Investigations on auto-antibodies in Alzheimer's and Parkinson's diseases, using defined neuronal cultures. J Neural Transm Suppl (1990) 0.81
Flupenthixol and trifluoperazine: a double-blind investigation in the treatment of schizophrenics. Br J Psychiatry (1971) 0.81
The growth-associated protein GAP-43 is increased in the hippocampus and in the gyrus cinguli in schizophrenia. J Mol Neurosci (2000) 0.81
Reduction of the small synaptic vesicle protein synaptophysin but not the large dense core chromogranins in the left thalamus of subjects with schizophrenia. Biol Psychiatry (1999) 0.81
Formulas for the quantitation of intrathecal IgG production. Their validity in the presence of blood-brain barrier damage and their utility in multiple sclerosis. J Neurol Sci (1994) 0.81
Antibodies in the cerebrospinal fluid of some Alzheimer's disease patients recognize amoeboid microglial cells in the developing rat central nervous system. Neuroscience (1991) 0.81
One-carbon metabolism and other biochemical correlates of cognitive impairment as visualized by principal component analysis. J Geriatr Psychiatry Neurol (2001) 0.81
Differences in cerebrospinal fluid gangliosides between "probable Alzheimer's disease" and normal aging. Aging (Milano) (1992) 0.81
Antibodies in the CSF of a Parkinson patient recognizes neurons in rat mesencephalic regions. Acta Physiol Scand (1986) 0.80
Determination of monoamine and monoamine metabolites in the human brain: post mortem studies in a group of suicides and in a control group. Acta Psychiatr Scand (1976) 0.80
Low B12 levels related to high activity of platelet MAO in patients with dementia disorders. A retrospective study. Acta Psychiatr Scand (1988) 0.79
Distribution of 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in human brain in relation to age, drug influence, agonal status and circadian variation. J Neural Transm (1981) 0.79
The effects of lithium carbonate in combination with tricyclic antidepressants in endogenous depression. A double-blind, multicenter trial. Acta Psychiatr Scand (1974) 0.79
The role of the polymorphic genes apolipoprotein E and methylene- tetrahydrofolate reductase in the development of dementia of the Alzheimer type. Dement Geriatr Cogn Disord (1999) 0.79
Disturbances of one-carbon metabolism in neuropsychiatric disorders: a review. Biol Psychiatry (1997) 0.79
Influence of depression and antidepressants on weight. Acta Psychiatr Scand Suppl (1981) 0.79
Homozygous thermolabile methylenetetrahydrofolate reductase in schizophrenia-like psychosis. J Neural Transm (Vienna) (1997) 0.79
Antinuclear factors in relation to age, sex, mental disease and treatment with phenothiazines. Acta Psychiatr Scand Suppl (1974) 0.78
Studies of the monoamine metabolism in the central nervous system in Jakob-Creutzfeldt disease. Acta Neurol Scand (1971) 0.78
Brain gamma-aminobutyrate aminotransferase (GABA-T) and monoamine oxidase (MAO) in patients with Alzheimer's disease. J Neural Transm Park Dis Dement Sect (1992) 0.78
Intracerebroventricular administration of GM1 ganglioside to presenile Alzheimer patients. Dement Geriatr Cogn Disord (1997) 0.78
Neurotransmitters in the brains of patients with dementia disorders. Dan Med Bull (1985) 0.78
The metabolism of some neurotransmitters in ageing and dementia disorders. Gerontology (1982) 0.78
Monoamine metabolites in cerebrospinal fluid and behavioral ratings in patients with early and late onset of Alzheimer dementia. Alzheimer Dis Assoc Disord (1989) 0.78
Brain and platelet monoamine oxidase in mental disorders 1. Schizophrenics and cycloid psychotics. Prog Neuropsychopharmacol (1980) 0.78
Grave lithium intoxication with fatal outcome. Acta Psychiatr Scand Suppl (1974) 0.77
Parenteral administration of GM1 ganglioside to presenile Alzheimer patients. Acta Neurol Scand (1990) 0.77
Vitamin B12-induced reduction of platelet monoamine oxidase activity in patients with dementia and pernicious anaemia. Eur Arch Psychiatry Clin Neurosci (1991) 0.77
Monoamine oxidase in platelets and brains of non-psychiatric and non-neurological geriatric patients. Med Biol (1979) 0.77